Advances in Clinical and Experimental Medicine

Title abbreviation: Adv Clin Exp Med
5-Year IF – 2.0, IF – 1.9, JCI (2024) – 0.43
Scopus CiteScore – 4.3
Q1 in SJR 2024, SJR score – 0.598, H-index: 49 (SJR)
ICV – 161.00; MNiSW – 70 pts
Initial editorial assessment and first decision within 24 h

ISSN 1899–5276 (print), ISSN 2451-2680 (online)
Periodicity – monthly

Download original text (EN)

Advances in Clinical and Experimental Medicine

2015, vol. 24, nr 6, November-December, p. 1007–1012

doi: 10.17219/acem/23439

Publication type: original article

Language: English

Download citation:

  • BIBTEX (JabRef, Mendeley)
  • RIS (Papers, Reference Manager, RefWorks, Zotero)

Risk Factors of Parathyroid Dysfunction in Elderly Patients with Chronic Kidney Disease Undergoing Hemodialysis

Weihua Li1,A,D, Shijun Zhang1,A,F

1 Department of Nursing, Qilu Hospital of Shandong University, China

Abstract

Background. Aberrant mineral metabolism and bone diseases, which are commonly seen in chronic kidney disease (CKD), have been considered to be the important causes of morbidity and decreased quality of life.
Objectives. We aimed to investigate the characteristics of calcium-phosphorus metabolism abnormalities and parathyroid dysfunction in elderly patients with chronic kidney disease undergoing hemodialysis.
Material and Methods. A total of 336 patients undergoing maintenance hemodialysis were divided into two age groups: elderly (≥ 65 years) and non-elderly (< 65 years). Before dialysis, fasting blood samples were initially collected, then hemoglobin (Hb), serum creatinine (Scr), blood urea nitrogen (BUN), calcium, phosphorus, intact parathyroid hormone (iPTH), high-sensitivity C-reactive protein (HsCRP) and albumin (Alb) were measured. Serums BUN, ultrafiltration volume, dialysis duration and body weight were measured after dialysis. Finally, wellestablished formulas were used to obtain the serum albumin corrected calcium (Ac-Ca) and urea removal index (Kt/V).
Results. Elderly patients accounted for 52.7% of our patients; essential hypertension accounted for 35.6% of the cause for chronic renal failure, followed by chronic glomerulonephritis (21.5%) and diabetes mellitus (19.8%) in the elderly group; while in the non-elderly group, 43.4% of the chronic renal failure was due to chronic glomerulonephritis, followed by diabetes mellitus (23.9%) and essential hypertension (12.6%). Significant differences were found in the dialysis duration, blood pressure, concentrations of serum BUN, Scr, P, iPTH, Alb, standard-protein nitrogen present rate (nPNA) and Hs-CRP between the 2 groups. The multiple logistic regression analysis showed that age, plasma phosphorus, albumin and nPNA were independent risk factors for secondary hyperparathyroidism in patients undergoing maintenance hemodialysis.
Conclusion. We conclude that most elderly patients undergoing hemodialysis experience hyperparathyroidism. The risk factors may include age and malnutrition but need further investigation.

Key words

hemodialysis, elderly, chronic renal failure, parathyroid hormone

References (19)

  1. Eknoyan G, Lameire N, Barsoum R, Eckardt KU, Levin A, Levin N, Locatelli F, MacLeod A, Vanholder R, Walker R, Wang H: The burden of kidney disease: improving global outcomes. Kidney Int 2004, 66, 1310–1314.
  2. Coen G, Ballanti P, Bonucci E, Calabria S, Costantini S, Ferrannini M, Giustini M, Giordano R, Nicolai G, Manni M, Sardella D, Taggi F: Renal osteodystrophy in predialysis and hemodialysis patients: comparison of histologic patterns and diagnostic predictivity of intact PTH. Nephron 2002, 91, 103–111.
  3. Freemont T, Malluche HH: Utilization of bone histomorphometry in renal osteodystrophy: demonstration of a new approach using data from a prospective study of lanthanum carbonate. Clin Nephrol 2005, 63, 138–145.
  4. Ho LT, Sprague SM: Percutaneous bone biopsy in the diagnosis of renal osteodystrophy. Sem Nephrol 2002, 22, 268–275.
  5. Lehmann G, Stein G, Huller M, Schemer R, Ramakrishnan K, Goodman WG: Specific measurement of PTH (1-84) in various forms of renal osteodystrophy (ROD) as assessed by bone histomorphometry. Kidney Int 2005, 68, 1206–1214.
  6. Madziarska K, Weyde W, Krajewska M, Zukowska Szczechowska E, Gosek K, Penar J, Klak R, Golebiowski T, Kozyra C, Klinger M: Elderly dialysis patients: analysis of factors affecting long-term survival in 4-year prospective observation. Int Urol Nephrol 2012, 44, 955–961.
  7. Tazza L, Di Napoli A, Bossola M, Valle S, Pezzotti P, Luciani G, Di Lallo D, Lazio Dialysis R: Ageing of patients on chronic dialysis: effects on mortality – a 12-year study. Nephrology, dialysis, transplantation: official publication of the European Dialysis and Transplant Association – European Renal Association 2009, 24, 940–947.
  8. Yilmaz MI, Saglam M, Caglar K, Cakir E, Sonmez A, Ozgurtas T, Aydin A, Eyileten T, Ozcan O, Acikel C, Tasar M, Genctoy G, Erbil K, Vural A, Zoccali C: The determinants of endothelial dysfunction in CKD: oxidative stress and asymmetric dimethylarginine. Am J Kidney Dis 2006, 47, 42–50.
  9. O’Flaherty D, Sankaralingam A, Scully P, Manghat P, Goldsmith D, Hampson G: The relationship between intact PTH and biointact PTH (1-84) with bone and mineral metabolism in pre-dialysis chronic kidney disease (CKD). Clin Biochem 2013.
  10. Canziani ME, Tomiyama C, Higa A, Draibe SA, Carvalho AB: Fibroblast growth factor 23 in chronic kidney disease: bridging the gap between bone mineral metabolism and left ventricular hypertrophy. Blood Purif 2011, 31, 26–32.
  11. Moe S, Drueke T, Cunningham J, Goodman W, Martin K, Olgaard K, Ott S, Sprague S, Lameire N, Eknoyan G: Kidney Disease: Improving Global O. Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 2006, 69, 1945–1953.
  12. Kurokawa K, Fukagawa M: Uremic bone disease: advances over the last 30 years. J Nephrol 1999, 12, Suppl 2, 63–67.
  13. Gal-Moscovici A, Popovtzer MM: New worldwide trends in presentation of renal osteodystrophy and its relationship to parathyroid hormone levels. Clin Nephrol 2005, 63, 284–289.
  14. Couttenye MM, D’Haese PC, Verschoren WJ, Behets GJ, Schrooten I, De Broe ME: Low bone turnover in patients with renal failure. Kidney Int Suppl 1999, 73, 70–76.
  15. Mucsi I, Hercz G: Relative hypoparathyroidism and adynamic bone disease. Am J Med Sci 1999, 317, 405–409.
  16. Kansal S, Fried L: Bone disease in elderly individuals with CKD. Adv Chronic Kidney Dis 2010, 17, 41–51.
  17. Almeida M, Han L, Martin-Millan M, Plotkin LI, Stewart SA, Roberson PK, Kousteni S, O’Brien CA, Bellido T, Parfitt AM, Weinstein RS, Jilka RL, Manolagas SC: Skeletal involution by age-associated oxidative stress and its acceleration by loss of sex steroids. J Biol Chem 2007, 282, 27285–27297.
  18. Drechsler C, Krane V, Grootendorst DC, Ritz E, Winkler K, Marz W, Dekker F, Wanner C, German D: Dialysis Study I. The association between parathyroid hormone and mortality in dialysis patients is modified by wasting. Nephrology, dialysis, transplantation: official publication of the European Dialysis and Transplant Association – European Renal Association 2009, 24, 3151–3157.
  19. Iwasaki Y, Yamato H, Nii-Kono T, Fujieda A, Uchida M, Hosokawa A, Motojima M, Fukagawa M: Insufficiency of PTH action on bone in uremia. Kidney Int Suppl 2006, 34–36.
© Wroclaw Medical University